Rh Negative Blood Type & Pregnancy: Risks, Treatment & Prevention

What Is RhD-Negative Blood Type and Rh Incompatibility?

RhD-negative blood type means your red blood cells lack the Rh D antigen, a protein found on the surface of red blood cells. If you are RhD-negative and your baby is RhD-positive (inherited from the father), your immune system may produce anti-D antibodies that can cross the placenta and attack the baby's blood cells in current or future pregnancies.

Everyone's blood belongs to one of the major blood groups: A, B, AB, or O. In addition to these groups, each person is either Rh-positive (RhD-positive) or Rh-negative (RhD-negative), depending on whether the Rh D protein is present on the surface of their red blood cells. The Rh factor is named after the Rhesus monkey, in which this protein was first discovered in 1940. Having an RhD-negative blood type is completely normal and does not cause any health problems on its own.

The significance of Rh status becomes particularly important during pregnancy. When an RhD-negative woman carries an RhD-positive baby, there is a possibility that small amounts of the baby's blood can enter the mother's bloodstream. This process is called fetomaternal hemorrhage and can occur during delivery, miscarriage, invasive prenatal procedures, or even spontaneously during late pregnancy. When this happens, the mother's immune system recognizes the baby's RhD-positive red blood cells as foreign invaders and produces anti-D antibodies to destroy them.

This immune response is called Rh sensitization or Rh isoimmunization. The initial exposure typically produces only a small number of IgM antibodies, which are too large to cross the placenta. However, once the immune system has been sensitized, any subsequent exposure to RhD-positive blood triggers a rapid and much stronger secondary immune response, producing large quantities of smaller IgG antibodies that readily cross the placental barrier. These IgG anti-D antibodies can then attack the red blood cells of an RhD-positive baby in a future pregnancy, causing a condition known as hemolytic disease of the fetus and newborn (HDFN).

Before the introduction of anti-D immunoglobulin prophylaxis in the late 1960s, Rh disease was a leading cause of perinatal mortality and morbidity. Today, thanks to routine screening and prevention programs, severe cases have become rare in countries with well-established prenatal care systems. The World Health Organization (WHO) lists anti-D immunoglobulin as an essential medicine, recognizing its critical role in preventing Rh disease worldwide.

How Common Is RhD-Negative Blood Type?

The prevalence of RhD-negative blood type varies significantly by ethnicity and geographic region. Among people of European descent, approximately 15% are RhD-negative, making it the most common population group affected. Among African Americans, about 8% are RhD-negative, while among people of Asian descent, only about 1% are RhD-negative. In the Basque population of Spain and France, the frequency is particularly high at approximately 30-35%.

Globally, it is estimated that about 15-17% of pregnancies involve an RhD-negative mother. In these pregnancies, the baby will be RhD-positive in about 60% of cases, depending on the father's blood type. If the father is homozygous RhD-positive (both copies of the Rh gene are positive), all children will be RhD-positive. If the father is heterozygous (one positive and one negative copy), there is a 50% chance for each pregnancy that the baby will be RhD-positive.

What Causes Rh Sensitization During Pregnancy?

Rh sensitization occurs when an RhD-negative mother's blood is exposed to RhD-positive fetal blood cells, most commonly during delivery but also during miscarriage, ectopic pregnancy, abdominal trauma, or invasive prenatal procedures such as amniocentesis.

Rh sensitization is triggered by fetomaternal hemorrhage, the transfer of fetal blood into the maternal circulation. While the placenta normally acts as a barrier between maternal and fetal blood, small amounts of fetal blood can cross into the mother's bloodstream during various events throughout pregnancy and delivery. The volume of fetal blood needed to trigger sensitization can be remarkably small; as little as 0.1 mL of RhD-positive fetal red blood cells can initiate an immune response in an RhD-negative mother.

The most significant fetomaternal hemorrhage typically occurs at the time of delivery, which is why Rh disease was historically more likely to affect second and subsequent pregnancies. During the separation of the placenta from the uterine wall, fetal blood cells enter the maternal circulation in nearly all deliveries. Studies have shown that approximately 50% of deliveries result in detectable fetomaternal hemorrhage, with about 1-2% involving volumes greater than 5 mL of fetal blood.

However, sensitization can also occur during pregnancy itself, and it is important to understand all the potential triggers so that preventive treatment can be given at the right time. The American College of Obstetricians and Gynecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) have identified several clinical situations that increase the risk of fetomaternal hemorrhage and therefore require anti-D prophylaxis.

Events That Can Cause Sensitization

A wide range of obstetric events and procedures can cause fetal blood cells to enter the maternal bloodstream. Healthcare providers need to be aware of all these situations to ensure that anti-D immunoglobulin is administered promptly. The following are the most common sensitizing events:

• Delivery: The most common cause of significant fetomaternal hemorrhage, occurring during both vaginal delivery and cesarean section
• Miscarriage: Both spontaneous miscarriage and surgical management can cause exposure to fetal blood
• Ectopic pregnancy: Surgical treatment or rupture can trigger sensitization
• Amniocentesis: This diagnostic procedure carries a risk of fetomaternal hemorrhage
• Chorionic villus sampling (CVS): Another prenatal diagnostic procedure that can disrupt the placental barrier
• Abdominal trauma: Falls, car accidents, or other injuries to the abdomen during pregnancy
• External cephalic version: The manual turning of a breech baby can cause fetomaternal hemorrhage
• Vaginal bleeding during pregnancy: Antepartum hemorrhage from any cause
• Invasive fetal procedures: Cordocentesis or intrauterine transfusion

How Does Rh Incompatibility Affect the Baby?

When a sensitized RhD-negative mother carries an RhD-positive baby, maternal anti-D antibodies cross the placenta and destroy the baby's red blood cells, causing fetal anemia. In mild cases this leads to neonatal jaundice; in severe cases it can cause hydrops fetalis, brain damage, or stillbirth if untreated.

Once an RhD-negative mother has been sensitized and has developed anti-D antibodies, these antibodies remain in her bloodstream permanently. In any subsequent pregnancy with an RhD-positive baby, the mother's immune system quickly recognizes the foreign Rh antigen and produces a large quantity of IgG anti-D antibodies. Unlike the larger IgM antibodies produced during initial sensitization, IgG antibodies are small enough to cross the placenta freely and enter the fetal circulation.

Once in the fetal bloodstream, these antibodies bind to the Rh D antigen on the surface of the baby's red blood cells, marking them for destruction by the fetal immune system. This process is called hemolysis, and the resulting condition is known as hemolytic disease of the fetus and newborn (HDFN). The severity of HDFN can vary enormously, from mild anemia and jaundice that requires no treatment to life-threatening fetal hydrops and death.

The rate at which the baby's red blood cells are destroyed determines the severity of the disease. The baby's bone marrow and other blood-forming organs (such as the liver and spleen) attempt to compensate by producing new red blood cells at an accelerated rate. When the destruction outpaces the production, the baby develops progressive anemia. The breakdown of red blood cells releases bilirubin, a yellow pigment that the placenta normally clears during pregnancy but that can accumulate rapidly after birth, causing jaundice.

In the most severe form of HDFN, profound anemia leads to hydrops fetalis, a condition characterized by massive fluid accumulation throughout the baby's body. The heart cannot pump effectively against the severe anemia, leading to congestive heart failure. Fluid accumulates in the abdomen (ascites), around the lungs (pleural effusion), around the heart (pericardial effusion), and in the skin (generalized edema). Without treatment, hydrops fetalis is almost always fatal.

Mild to Moderate HDFN

Most cases of HDFN today are mild to moderate, particularly because anti-D prophylaxis has dramatically reduced the number of severely sensitized women. In mild cases, the baby may be born with slight anemia and develop jaundice within the first 24 hours of life. The jaundice results from the continued destruction of the baby's red blood cells after birth and the accumulation of bilirubin. Phototherapy (light therapy) is usually sufficient to treat mild to moderate jaundice by breaking down bilirubin in the skin.

In moderate cases, the baby may need closer monitoring and more intensive phototherapy. Occasionally, exchange transfusion may be required, a procedure in which the baby's blood is gradually replaced with compatible donor blood to remove both the excess bilirubin and the circulating maternal antibodies. Without treatment, severely elevated bilirubin levels can cause kernicterus, a form of brain damage resulting from bilirubin deposition in the brain tissue.

Severe HDFN and Hydrops Fetalis

Severe HDFN is now rare in countries with routine anti-D prophylaxis programs but remains a significant concern in regions where preventive treatment is not widely available. Severe disease is characterized by profound fetal anemia that develops during pregnancy, before the baby is born. The fetal bone marrow cannot keep up with the rate of red blood cell destruction, and the liver and spleen enlarge dramatically as they attempt to produce additional red blood cells (a process called extramedullary hematopoiesis).

If left untreated, severe fetal anemia progresses to hydrops fetalis. Modern prenatal monitoring using middle cerebral artery (MCA) Doppler ultrasound can detect fetal anemia non-invasively by measuring the peak velocity of blood flow in the baby's brain. When anemia is detected, intrauterine blood transfusion can be performed, a highly specialized procedure in which compatible red blood cells are transfused directly into the fetal circulation through the umbilical cord. This procedure can be repeated as needed and has transformed the prognosis for severely affected babies.

How Is Rh Incompatibility Diagnosed?

Rh incompatibility is diagnosed through routine blood tests at the first prenatal visit, which determine your blood type, Rh factor, and whether you have existing anti-D antibodies. If you are RhD-negative, additional tests including cell-free fetal DNA testing and antibody screening are performed throughout pregnancy.

The diagnosis of Rh incompatibility begins with routine prenatal blood testing, one of the first and most important tests performed when you begin prenatal care. This blood test, which is recommended by all major obstetric organizations worldwide, determines your ABO blood group and your Rh D status. If you are found to be RhD-negative, additional testing is initiated to assess the risk of Rh disease and guide preventive treatment.

At the same time as your blood type is determined, an antibody screening test (also called an indirect Coombs test or indirect antiglobulin test) is performed. This test checks your blood for the presence of anti-D antibodies and other irregular blood group antibodies. If you have never been sensitized, the antibody screen will be negative, and the focus of care shifts to preventing sensitization through anti-D prophylaxis. If the antibody screen is positive for anti-D antibodies, it means you have already been sensitized, and the pregnancy will require closer monitoring.

For RhD-negative women with negative antibody screens, the antibody test is typically repeated at 28 weeks of pregnancy, before the routine anti-D injection is given. This ensures that sensitization has not occurred earlier in the pregnancy. In women who are already sensitized, antibody levels (titers) are monitored regularly throughout pregnancy to assess the severity of the immune response and guide decisions about fetal monitoring and intervention.

Cell-Free Fetal DNA Testing

One of the most significant advances in the management of Rh-negative pregnancies is non-invasive prenatal testing (NIPT) for fetal RhD status. During pregnancy, small fragments of the baby's DNA circulate in the mother's blood. Using a simple maternal blood sample, typically drawn around weeks 10-12 of pregnancy, laboratories can determine whether the baby is RhD-positive or RhD-negative with an accuracy exceeding 99%.

This test is transformative because it allows healthcare providers to identify which RhD-negative women actually need anti-D prophylaxis. If the baby is confirmed to be RhD-negative, there is no risk of Rh incompatibility, and anti-D injections are unnecessary. This eliminates the use of a blood-derived product in women who do not need it and conserves the global supply of anti-D immunoglobulin. Many countries, including Denmark, the Netherlands, and parts of the United Kingdom, have already incorporated cell-free fetal DNA testing into their routine prenatal care protocols.

Monitoring a Sensitized Pregnancy

If you are already sensitized (anti-D antibodies detected), your pregnancy will be managed as high-risk and monitored closely by a specialist in maternal-fetal medicine. The key components of monitoring include regular antibody titer measurements, ultrasound surveillance, and Doppler assessment of fetal blood flow.

Anti-D antibody titers are measured at regular intervals, typically every 2-4 weeks. A rising titer indicates an increasing immune response and a greater risk of fetal anemia. When titers exceed a critical threshold (usually 1:16 or 4 IU/mL, depending on the laboratory), fetal Doppler monitoring is initiated.

Middle cerebral artery (MCA) Doppler is the gold standard for non-invasive detection of fetal anemia. When a baby is anemic, the blood becomes thinner and flows faster through the brain's blood vessels. By measuring the peak systolic velocity (PSV) of blood flow in the MCA, doctors can estimate the degree of fetal anemia with high sensitivity. An elevated MCA-PSV above 1.5 multiples of the median (MoM) for gestational age suggests moderate to severe anemia and may indicate the need for intrauterine transfusion.

How Is Rh Incompatibility Treated and Prevented?

Rh incompatibility is prevented with anti-D immunoglobulin (RhoGAM) injections given at 28 weeks of pregnancy and within 72 hours after delivery. If sensitization has already occurred, treatment focuses on monitoring the baby with Doppler ultrasound and performing intrauterine blood transfusions if severe anemia develops.

The management of Rh incompatibility falls into two distinct categories: prevention (for women who have not yet been sensitized) and treatment (for pregnancies where sensitization has already occurred). Prevention is by far the preferred approach, as it is simple, highly effective, and safe. Once sensitization has occurred, management becomes much more complex and requires specialized care.

The cornerstone of prevention is anti-D immunoglobulin, a purified blood product containing antibodies against the Rh D antigen. When injected into an RhD-negative mother, these antibodies rapidly seek out and destroy any RhD-positive fetal red blood cells that have entered her circulation, before her own immune system has a chance to recognize them and mount an immune response. By eliminating the foreign cells before sensitization can occur, anti-D immunoglobulin effectively prevents the development of anti-D antibodies. This principle is known as passive immunization.

The introduction of anti-D immunoglobulin prophylaxis in the late 1960s represents one of the greatest success stories in modern obstetrics. Before its widespread use, Rh sensitization occurred in approximately 16% of RhD-negative women carrying RhD-positive babies. With routine antenatal and postnatal prophylaxis, the sensitization rate has been reduced to less than 0.1-0.3%, a reduction of over 99%. This has prevented countless cases of HDFN, hydrops fetalis, and perinatal death.

Routine Anti-D Prophylaxis Schedule

The standard anti-D prophylaxis protocol recommended by ACOG, RCOG, and other international guidelines involves two key components: routine antenatal prophylaxis (RAADP) and postnatal prophylaxis. The exact dosing and timing can vary slightly between countries, but the fundamental principles are the same.

Routine antenatal anti-D prophylaxis (RAADP) involves administering anti-D immunoglobulin at approximately 28 weeks of pregnancy. Some protocols use a single larger dose at 28 weeks, while others give two smaller doses at 28 and 34 weeks. Both approaches are effective. This injection provides passive antibody protection during the third trimester, when the risk of spontaneous fetomaternal hemorrhage increases as the placenta matures and the baby grows.

Postnatal prophylaxis is given within 72 hours of delivery if the baby is confirmed to be RhD-positive. A blood sample from the umbilical cord is tested to determine the baby's blood type. If the baby is RhD-positive, the mother receives an anti-D injection. In some countries, a Kleihauer-Betke test or flow cytometry is performed to estimate the volume of fetomaternal hemorrhage, and additional doses of anti-D immunoglobulin are given if a large bleed is detected.

Anti-D for Sensitizing Events

In addition to routine antenatal and postnatal prophylaxis, anti-D immunoglobulin must be administered after any event during pregnancy that could cause fetomaternal hemorrhage. Timing is critical: the injection should be given as soon as possible and within 72 hours of the event for maximum effectiveness. If more than 72 hours have passed, the injection should still be given, as some benefit may still be obtained up to 10 days after exposure.

Common situations requiring anti-D injection include vaginal bleeding at any stage of pregnancy, miscarriage or termination of pregnancy, ectopic pregnancy, abdominal trauma, amniocentesis, chorionic villus sampling, external cephalic version, and any other invasive obstetric procedure. Healthcare providers should maintain a high index of suspicion and err on the side of giving anti-D immunoglobulin when in doubt.

Treatment of Established Rh Disease

When an RhD-negative mother is already sensitized, anti-D immunoglobulin cannot reverse the sensitization. Management focuses on close monitoring of the fetus and intervention when necessary. The primary tools for managing established Rh disease are:

• Serial antibody titer monitoring: Anti-D levels are measured every 2-4 weeks to track the immune response
• MCA Doppler ultrasound: Weekly or biweekly scans to detect fetal anemia non-invasively
• Intrauterine blood transfusion: Direct transfusion of compatible red blood cells into the fetal circulation when severe anemia is detected
• Early delivery: Planned delivery at 37-38 weeks or earlier if the baby's condition deteriorates
• Neonatal care: Phototherapy, exchange transfusion, and supportive care after birth

Intrauterine blood transfusion (IUT) is the most important intervention for severe fetal anemia. First performed successfully in the 1960s and refined significantly since then, IUT involves inserting a fine needle through the mother's abdomen and into the umbilical vein, guided by ultrasound. Compatible, O-negative, irradiated red blood cells are slowly transfused into the fetal circulation. The procedure can be repeated every 2-4 weeks as needed. In experienced centers, the success rate of IUT exceeds 90%, and the procedure has dramatically improved survival rates for severely affected babies.

What Happens During Prenatal Care If You Are Rh Negative?

If you are RhD-negative, your prenatal care includes blood type confirmation and antibody screening at the first visit, possible cell-free fetal DNA testing at 10-12 weeks, repeat antibody screening and routine anti-D injection at 28 weeks, and postnatal anti-D within 72 hours if the baby is RhD-positive.

Being RhD-negative during pregnancy is very common and well understood by healthcare providers worldwide. The management of an RhD-negative pregnancy is straightforward and follows clear evidence-based guidelines. Most RhD-negative women have completely uncomplicated pregnancies when the appropriate preventive measures are taken. Understanding the timeline of care can help you feel more prepared and informed throughout your pregnancy.

At your first prenatal visit, a blood sample is taken to determine your blood type and Rh status. This is done regardless of whether you know your blood type, as laboratory confirmation is essential. An antibody screening test is performed simultaneously to check for existing anti-D or other irregular antibodies. The results of these tests guide the plan for your entire pregnancy. If you are RhD-negative with a negative antibody screen, you will be offered anti-D prophylaxis as described above.

In countries that have implemented cell-free fetal DNA testing for fetal RhD status, a blood sample may be taken around weeks 10-12 of pregnancy. This test determines whether the baby is RhD-positive or RhD-negative by analyzing fragments of the baby's DNA in your bloodstream. If the baby is confirmed to be RhD-negative, no anti-D injections are needed, and your pregnancy care continues as normal. If the baby is RhD-positive or the test is inconclusive, you will receive anti-D prophylaxis as recommended.

At approximately 28 weeks, your antibody screen is repeated to confirm that you have not become sensitized. If the screen remains negative, you receive the routine anti-D immunoglobulin injection. Some women notice mild soreness at the injection site, which resolves within a day or two. The anti-D provides protection for the remainder of the pregnancy, as the third trimester is when the risk of spontaneous fetomaternal hemorrhage is highest.

After your baby is born, a cord blood sample is taken from the umbilical cord to determine the baby's blood type and Rh status. If the baby is RhD-positive, you receive another anti-D injection within 72 hours of delivery. This postnatal dose mops up any fetal red blood cells that entered your circulation during delivery and prevents sensitization before your next pregnancy. If the baby is RhD-negative, no postnatal anti-D is needed.

Special Considerations

Some situations during pregnancy require additional attention for RhD-negative women. If you experience vaginal bleeding at any point during your pregnancy, you should contact your healthcare provider promptly. Bleeding can indicate that fetal blood cells have entered your circulation, and an extra dose of anti-D immunoglobulin may be needed. Similarly, if you are involved in any kind of abdominal trauma, such as a car accident or a fall, you should seek medical attention and mention your RhD-negative status.

If you need any invasive prenatal procedures such as amniocentesis or chorionic villus sampling, your healthcare team will ensure that anti-D immunoglobulin is administered at the time of the procedure. For women who have a miscarriage or ectopic pregnancy, anti-D should be given regardless of gestational age, although the dose may be smaller for very early pregnancy losses (before 12 weeks).

Does Rh Incompatibility Affect Future Pregnancies?

If you receive proper anti-D prophylaxis during each pregnancy, Rh incompatibility will not affect future pregnancies. However, if sensitization has occurred, each subsequent RhD-positive pregnancy carries an increasing risk of hemolytic disease of the newborn, as the immune response becomes stronger with repeated exposure.

One of the most important aspects of Rh incompatibility to understand is its cumulative nature. The immune system has immunological memory, meaning that once it has been sensitized to the Rh D antigen, it remembers this encounter permanently. This is the same mechanism that allows vaccines to provide long-lasting protection against infections, but in the case of Rh disease, this memory works against the mother and her future babies.

In an unsensitized RhD-negative woman who receives appropriate anti-D prophylaxis with each pregnancy, the risk of sensitization remains extremely low, less than 0.3%. This means that with proper care, you can have multiple pregnancies without developing Rh disease. However, it is essential that anti-D immunoglobulin is given during every pregnancy with an RhD-positive baby, not just the first one. Each pregnancy represents a new potential exposure to RhD-positive fetal blood cells, and each requires its own prophylaxis.

For women who have already been sensitized, the picture is different. With each subsequent RhD-positive pregnancy, the immune response becomes faster and stronger due to immunological memory. The first sensitized pregnancy may result in only mild HDFN, but subsequent pregnancies tend to produce more severe disease. The antibody titers typically rise faster and reach higher levels with each successive pregnancy, and the onset of fetal anemia tends to be earlier. This is why prevention of sensitization is so much more important than treatment of established disease.

For sensitized women who wish to have more children, preconception counseling with a maternal-fetal medicine specialist is strongly recommended. The father's Rh genotype can be tested to determine whether future babies might be RhD-negative (and therefore unaffected). If the father is heterozygous for the RhD gene, there is a 50% chance that each baby will be RhD-negative. Cell-free fetal DNA testing early in pregnancy can then determine the baby's Rh status, allowing appropriate monitoring to be planned.

When Should You Contact Your Healthcare Provider?

Contact your healthcare provider immediately if you are RhD-negative and experience vaginal bleeding, abdominal trauma, or if you think you may have missed an anti-D injection. Seek emergency care for heavy bleeding, severe abdominal pain, or signs of preterm labor.

While Rh incompatibility is a well-managed condition in modern prenatal care, there are certain situations where you should contact your healthcare provider promptly. Being proactive about reporting potential sensitizing events ensures that you receive anti-D immunoglobulin within the critical 72-hour window, maximizing its effectiveness.

You should contact your healthcare provider or midwife if you experience any of the following during pregnancy:

• Vaginal bleeding: Any amount of bleeding during pregnancy, whether spotting or heavier flow, should be reported
• Abdominal trauma: Falls, car accidents, sports injuries, or any blow to the abdomen
• Missed anti-D injection: If you think your scheduled anti-D injection was not given or was delayed
• Concerns about your Rh status: If you are unsure whether your blood type has been tested or if you need anti-D

Frequently Asked Questions About Rh Negative Pregnancy